Epstein-Barr virus (EBV) early-antigen (EA) serologic profile was examined in conjunction with peripheral blood EBV DNA load, to assess its value in evaluating the risk of developing posttransplantation lymphoproliferative disease (PTLD). The cohort included 26 pediatric recipients of solid-organ transplants, 6 of whom developed PTLD. All 6 patients had high peripheral blood EBV DNA loads. Of the remaining 20 patients who did not develop PTLD, 14 had high EBV DNA loads, and 6 had low EBV DNA loads. None of the patients who developed PTLD had significant EA immunoglobulin G (IgG) titers. However, all 14 patients with high EBV DNA loads and without PTLD had high EA IgG titers, either at the time of initial high EBV DNA load or during the ensuing weeks. Here, we report that EBV DNA load analysis, combined with EA serologic analysis, is a potentially useful prognostic marker for evaluating the risk of developing PTLD. [1] [2] [3] [4] [5] [6] . These patients become susceptible to B cell lymphoproliferative disease, a malignancy caused by uncontrolled expansion of EBV-infected B cells. Transplant recipients are especially at risk because of the aggressive immunosuppressive medication they receive to control graft rejection [7] [8] [9] . The incidence of posttransplantation lymphoproliferative disease (PTLD) is variable, ranging from 1% to 132%, depending on the organ transplanted, the nature and/or severity of the accompanying immunosuppressive regimen, and the patient's
EBV serostatus before transplantation [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Because primary EBV infection occurring early after transplantation surgery constitutes the main risk factor for developing PTLD and because ∼50% of children are EBV seropositive, compared with 90% of adults, pediatric transplant recipients run a significantly higher risk of developing PTLD than do their adult counterparts [23, 24] .
Diagnosis of PTLD is often challenging because of the practical difficulty in distinguishing this syndrome from rejection [25] [26] [27] . Clinical symptoms and the results of microscopic evaluation of biopsy specimens can be similar in both cases. Because a diagnosis of PTLD would necessitate a decrease in immunosuppressive medication, whereas the onset of rejection would demand a more aggressive immunosuppressive regimen, proper patient treatment depends on accurate laboratory markers to distinguish the 2 diseases. In addition, if preemptive therapy is to be adopted as an efficacious method of preventing PTLD, then reliable markers for specifically assessing the risk of developing PTLD must be sought.
In 1994, culture and polymerase chain reaction (PCR)-based tests were developed for evaluation of EBV DNA load in peripheral blood mononuclear cells (PBMCs) from a small cohort of pediatric transplant recipients [28] . The results of that study and others [29] [30] [31] [32] indicated that EBV DNA load determination in PBMCs, although valuable as a negative predictive marker of PTLD, was less accurate as a positive indicator. Therefore, it became necessary to seek other parameters that could be used in conjunction with assessment of EBV DNA load, to better predict the risk of developing EBVinduced PTLD.
In the present study, we specifically sought to examine EBV early-antigen (EA) IgG titers, because, as is currently the case with increased EBV DNA load, the presence of antibody to EA has been thought historically to be a marker of active EBV infection [33, 34] ; however, its significance in transplant recipients is questionable, because they are immunosuppressed and may not be able to muster an immune response in spite of active EBV infection. Essentially, our goal was to assess the usefulness of EA serologic testing in transplant recipients, because this test has been regularly requested as part of the evaluation and follow-up of our pediatric patient group. Our primary objective was to evaluate EA serum titers retrospectively in our cohort of transplant recipients with high EBV DNA loads and to determine whether EA titers differed quantitatively between the patients who developed PTLD and those who did not. We hoped to increase the positive predictive value (PPV) of our EBV DNA load test, to be able to more accurately screen for those patients who are at risk of developing PTLD.
PATIENTS AND METHODS

Patient selection.
The present study is a retrospective analysis of pediatric solid-organ transplant recipients treated at SainteJustine Hospital (Montreal); the study was performed in accordance with the Helsinki Declaration and received approval by the Sainte-Justine Hospital Research Ethics Committee. From early 1991 through the end of 1999, 84 livers, 60 kidneys, and 23 hearts were transplanted into pediatric recipients, ranging in age from 1 month to 19 years. Of these 167 patients, 54 (44 liver-transplant recipients, 6 kidney-transplant recipients, and 4 heart-transplant recipients) were tested for EBV DNA load at various time points after transplantation. Twenty-six of the patients were selected for this study on the basis of records indicating that a more complete follow-up had occurred during the first year after transplantation. The study group also included some of the patients for whom data had been obtained for a prior study [28] . All samples that predated 1994 were obtained 0, 3, 6, and 12 months after transplantation. Thereafter, the protocol at Sainte-Justine Hospital was changed so that samples were obtained from high-risk patients, defined as those who were donor positive/recipient negative (D + /R Ϫ ) for EBV, at 1-2 week intervals, continuously throughout the first 6 months after transplantation, and according to clinical evolution thereafter. One of the patients included in our cohort was a kidney-transplant recipient referred to us from the Montreal Children's Hospital for EBV DNA load analysis. All samples were tested for EBV DNA load and EA serologic profile as part of the standard patient work-up. A total of 319 blood specimens were processed for the 26 patients studied.
The results of a previous study [28] allowed us to set the high-risk standard at у1 EBV genomes/1000 PBMCs. Twenty patients were selected on the basis of their having a high relative risk of developing PTLD, as determined by EBV DNA load (figure 1). Six other patients were selected as representative control subjects on the basis of low EBV DNA load results at all times sampled. These 26 patients were monitored for an average of 15.5 months (range, 1.5-44.0 months) after transplantation. The group consisted of 23 liver-transplant recipients, 2 kidney-transplant recipients, and 1 heart-transplant recipient. The clinical profiles for all patients are summarized in table 1. The patients were divided into 3 groups: (1) patients with high peripheral blood EBV DNA loads who developed PTLD during the study period (6 patients), (2) patients with high peripheral blood EBV DNA loads who did not develop PTLD during the study period (14 patients), and (3) control patients with low peripheral blood EBV DNA loads who did not develop PTLD during the study period (6 patients).
Immunosuppression protocol. Until 1998, all transplant recipients at Sainte-Justine Hospital received intravenous (iv) cyclosporine, prednisone, and azathioprine (or, for kidneytransplant recipients, mofetil mycophenolate [MMF] , also known as Cellcept [Roche]) as initial immunosuppressive treatment. Oral cyclosporine administered as 3 daily doses was introduced at the end of the first week. Initial trough cyclosporine levels were adjusted to 350-400 ng/mL during the first 2 weeks, to 250-300 ng/mL from week 2 through week 4, and to 100-150 ng/mL after the third month. In 1998, iv administration of cyclosporine was abandoned in favor of oral or nasogastric administration of cyclosporine on the first day after transplantation. Azathioprine was administered at a dose of 1-2 mg/kg/ day, according to the leukocyte count, and was continued long term. The prednisone dosage was decreased to 0.3 mg/kg/day by the end of the first month. In patients with normal transaminase levels, an alternate-day prednisone regimen was achieved by 6 months, and the use of corticosteroids was discontinued at 1 year. Only patient 10 received tacrolimus (FK506) instead of cyclosporine (Neoral; Novartis) in the primary immunosuppressive regimen because of a high risk of liver malfunction in the event of rejection. Acute cellular rejection episodes were all documented by biopsy before therapy, which included an iv bolus of methylprednisolone (600 mg/m 2 ) for 3 consecutive days, followed by weaning to prednisone (2 mg/kg/day) over the course of 7-10 days. Five patients were switched from cyclosporine to FK506, because of refractory acute rejection in 2 cases (patients 18 and 20) and because of chronic rejection in 3 cases (patients 3, 5, and 11; Ϫ ) were given either iv immunoglobulin (IVIG) or CMV immunoglobulin (Cytogam; MedImmune). Ganciclovir was not used as primary prophylaxis against CMV infection. Preparation of DNA from PBMCs. Approximately 2 mL of peripheral blood was obtained and processed as described elsewhere [28] . In brief, PBMCs were isolated by standard density centrifugation by use of Ficoll-Paque solution (Pharmacia Biotech). The cells were pelleted, washed twice in PBS, and NOTE. A, azathioprine; ALG, antilymphocyte globulin; ATG, antithymocyte globulin; C, cyclosporine; EBV, Epstein-Barr virus; NA, not applicable; OKT3, anti-CD3 antibody preparation; P, prednisone; ++, appearance of signal following hybridization with a digoxigenin-labelled probe; +++, appearance of signal on ethidium bromide-stained gel.
stored at Ϫ80ЊC in aliquots containing cells. The cell 6 1 ϫ 10 pellet was resuspended in sterile deionized water (initial concentration, 50,000 PBMCs/20 mL), boiled for 10 min, and cooled on ice. All PBMC samples were initially screened qualitatively for EBV DNA by performing 3 amplifications of 50,000 cells each. When the amplification reaction attained a detection value of у1 EBV genomes/50,000 PBMCs, the cell suspension was further diluted to permit amplifications of 10,000 and 1000 cells/tube. Thus, a sample that was positive according to the qualitative test (у1 EBV genomes/50,000 PBMCs) would henceforth be assayed by the semiquantitative test, whereby , , and cells were amplified. 1 ϫ 50,000 2 ϫ 10,000 2 ϫ 1000 PCR assay and detection of amplified product. The primer pair and the oligonucleotide probe were selected from a highly conserved region of the EBV BMLF1 open-reading frame, as described by Pedneault et al. [35] . The predicted sequence length of the amplified product is 304 bp. The PCR was performed in duplex with a second set of primers (GH26 and GH27), as described by Scharf et al. [36] , which define a DNA fragment within the HLA-DQa gene, yielding a 242-bp segment to signal the presence of cellular DNA. PCR amplification was performed essentially as described by Savoie et al. [28] .
Ten microliters of each amplified product was loaded onto a 1.8% agarose gel containing ethidium bromide. After electrophoresis, the gel was treated with alkaline phosphatase, neutralized, Southern blotted, and prehybridized according to standard protocols. Hybridization was performed overnight at 65ЊC with 10 pmol of the oligonucleotide probe labeled with digoxigenin (DIG)-11-dUTP, a component of Roche's DIG Oligonucleotide 3 -End-Labeling Kit, per milliliter of hybridization buffer. Detection of bound probe was performed with an anti-DIG detection kit and a chemiluminescent substrate (CSPD; Roche Diagnostics). The bands were visualized after a 2-h exposure on Kodak XAR film at room temperature.
Serologic analysis. The indirect immunofluorescence technique was used for detection of antibodies to the EBV EA complex [37] . To prepare slides, Raji cells were grown to log phase at 37ЊC in RPMI 1640 medium (Invitrogen) containing 10% fetal bovine serum and were induced chemically by addition of 20 ng/mL PMA (Sigma-Aldrich Canada). At 48 h after induction, the cells were harvested by centrifugation, washed twice in PBS, smeared onto glass slides, and air dried. Smears were then fixed in acetone (5 min at 4ЊC), air dried, and stored dessicated at Ϫ20ЊC. More recently, commercially available slides obtained from GRANBIO have replaced the slides prepared inhouse. Three dilutions of the patients' serum samples were used (1:10, 1:100, and 1:1000). Fluorescein isothiocyanate-conjugated goat antibodies to human IgG (Jackson ImmunoResearch [distributed by Bio/Can Scientific]) were used in the secondary step. The slides were read with a Zeiss UV microscope (model 16A) equipped with epifluorescence.
For assessing titers of the EBV nuclear antigens (EBNAs), standard anticomplement immunofluorescence was used on acetone-methanol-fixed Raji cells [38] , an African Burkitt line known to express EBNA1-EBNA5. Specific antibodies to EBNA2 were detected by use of anticomplement immunofluorescence on EBNA2-transfected BJA-B cells (a gift from Prof. Elliott Kieff, Harvard Medical School, Boston, MA). Antibodies to the viral capsid antigen (VCA) were detected by standard indirect immunofluorescence [39] on the B95-8 marmoset cell line.
Diagnosis of PTLD. PTLD was diagnosed on the basis of histologic examination of biopsy or autopsy material, according to published criteria [40] .
Statistical analysis. Standard clinimetric indices were calculated by use of the serial method, EA test performance was assessed only for EBV DNA load tests with positive results. For all indices, exact 95% confidence intervals corrected for asymmetry were calculated and used for comparison.
RESULTS
Primary EBV infection and development of PTLD. Of the 26 patients studied, 20 were EBV seronegative before transplantation (table 1). The 6 patients who developed PTLD were all EBV seronegative at the time of transplantation, and all underwent primary infection within a range of 4-28 weeks after transplantation, as documented by PCR analysis. Table 2 lists the immunosuppressive regimens of all high-risk patients included in the present study. Clinical information with regard to antirejection therapy and outcome in patients with PTLD is provided in table 3.
EBV DNA load determination and EA serologic analysis. On the basis of threshold EBV DNA load results from a previous study [28] , in which a value of у1 EBV genomes/1000 PBMCs was associated with a high risk of developing PTLD, we determined that 20 of the 26 patients selected were at high risk of developing PTLD. It was noted that non of the 6 patients who developed PTLD had a high EA antibody titer (р10 in all cases) at the time of initial high EBV DNA load or PTLD diagnosis (tables 2 and 4). Of the 14 patients without PTLD, all had high EA antibody titers (12 patients had titers у1000, and 2 patients had titers у100; table 2). Of the 14 patients with EA antibody titers у100, 7 had EA antibodies at the time of the initial high EBV DNA load, and 7 others developed EA antibodies during the ensuing weeks (6, 9, 11, and 36 weeks later for patients 8, 25, 6, and 18, respectively, who did not receive IVIG [mean, 15.2 weeks]; and 23, 28, and 39 weeks later for patients 7, 9, and 10, respectively, who were receiving IVIG or CMV immunoglobulin for CMV prophylaxis at the time of high EBV DNA load determination [mean, 30.0 weeks]; table 2). In the low-risk group ( ) with a EBV DNA load n p 6 of !1 EBV genome/1000 PBMCs, patients did not develop PTLD, nor did they demonstrate significant EA antibody titers. Figure 2 shows representative plots of EBV DNA load versus EA antibody titers for 4 of the patients who developed PTLD and for 4 other high-risk patients who did not develop PTLD. In the 4 patient graphs featured in figure 2A , an arrow points to the time at which PTLD was first diagnosed in the individual patients. Patient 24 is unique in demonstrating EA antibody reactivity, albeit at low titers, both before and at the time of PTLD detection. These titers increased significantly several weeks after the donor kidney was removed and the immunosuppression regimen was completely arrested. Low antibody levels were also detected in patient 26, 3 weeks after initial high EBV DNA load and concurrent PTLD diagnosis, probably resulting from a relaxation of the immunosuppressive regimen after PTLD detection. Analysis of these 2 cases indicated that low EA IgG titers do not correlate with protection. Patient 22 is interesting because the patient's EBV DNA load fluctuated between high and low values. This patient had an extremely low lymphocyte count, which led to inaccurate calculation of PBMC counts from which to perform the amplifications. Interestingly, this patient's PTLD was localized to the skin. Figure 2B shows the range of responses observed in patients with very high EBV DNA load who did not develop PTLD. Five of the 7 patients already had high EA IgG titers at or before the time of initial high EBV DNA load, as represented in the graph for patient 5. For patient 6, the EA IgG response was delayed by 11 weeks relative to the initial high EBV DNA load peak, whereas, for patient 9, high EA IgG titers appeared at 28 weeks. The latter patient had been receiving IVIG therapy. Patients 7 and 10, who were also receiving IVIG, did not develop high EA IgG titers until 23 and 39 weeks, respectively, after initial detection of high EBV DNA load. For patient 10, the high EBV DNA load peak seemed to be transient and was only detectable after hybridization with a labeled probe. This patient's second high EBV DNA load peak appeared concurrently with a high EA IgG titer.
Because the present study was retrospective, it allowed us to compare EBV DNA load with outcome (i.e., appearance of PTLD). We noted that, for a total of 13 patients, the amplified EBV band was visible directly on the ethidium bromide-stained gel. Although further amplification of the signal was not required for visibility, hybridization with a DIG-labeled probe was performed to authenticate the signal. All 6 patients who developed PTLD were in this group. This observation allowed us to redefine the high-risk threshold at у1 genomes/1000 cells on an ethidium bromide-stained gel. Thus, the PPV of high EBV DNA load alone is 46.2%. As shown in table 2, 8 patients (patients 1, 2, 3, 6, 9, 22, 24 , and 26) lacked significant EA IgG titers at the initial EBV DNA load spike. Six of the 8 patients (patients 1, 2, 3, 22, 24, and 26) developed PTLD, but the other 2 (patients 6 and 9) did not. Thus the PPV for the EA testdefined as the absence of significant EA IgG-in patients with very high EBV DNA loads is 75%, an increase of 28.8% over high EBV DNA load determination alone. The negative predictive value for the EA test-defined as the presence of significant EA IgG titers in patients with very high EBV DNA loads-is 100% (table 4) .
Serologic responses to other EBV antigens. Table 5 summarizes the results of a preliminary experiment performed early in the present study. The goal was to elucidate the EBV-specific serologic response in patients with high EBV DNA loads, both with and without PTLD. Standard anticomplement immunofluorescence on Raji cells was used for detection of antibodies to EBNA1-EBNA5. Results indicate that the range of serologic responses for both groups of patients was too wide for this standard EBNA staining to be useful as a differential marker. For EBNA2, the PTLD-negative patients had a wide range of serologic responses, thus barring the use of their results as a differential marker, even though the PTLD-positive patients had a narrow range of serologic responses. High reactivity to VCA was present in both groups, making it impossible to distinguish high-risk from low-risk patients. Only in the case of EA IgG was a clear demarcation in serologic titers noted between the 2 groups. Data from healthy EBV-seropositive individuals are also provided for reference purposes.
DISCUSSION
PTLD is a severe complication of organ transplant in allograft recipients treated with immunosuppressive drugs (such as cyclosporine, FK506, and OKT3 monoclonal antibody), all of which target the T cell response [41] [42] [43] [44] [45] [46] [47] [48] . Being EBV seronegative before transplantation constitutes a significant risk factor for recipients, especially children, approximately one-half of whom are nonimmune to EBV at the time of transplantation. The present study was retrospective, selecting a cohort of 26 patients, 20 of whom were originally judged to be at high risk of developing PTLD on the basis of EBV DNA load in PBMCs (у1 EBV genomes/1000 PBMCs; table 2). Furthermore, 15 of the 20 high-risk patients in our cohort were EBV seronegative at the time of transplantation. All seronegative patients experienced seroconversion an average of 8.9 weeks after transplantation, which correlates well with published reports of seroconversion occurring 2.5-12 weeks after transplantation [49] . Six of the 20 high-risk patients developed PTLD after primary EBV infection in the months after transplantation. However, 9 other EBV-seronegative patients with high EBV DNA loads did not develop PTLD.
As shown in table 2, 6 patients received ALG, ATG, or OKT3 as antirejection agents. These agents have all been associated with a highly increased risk of developing PTLD [8, 16, 21, 48, [50] [51] [52] . Of the 6 patients in our cohort who developed PTLD, 4 received ALG (10 days), ATG (6 days), OKT3 (35 days), or ALG (8 days) plus OKT3 (23 days). Of the 14 high-risk patients who did not develop PTLD, only 2 received ALG (7 and 10 days, respectively). One of those 2 patients was EBV seropositive at the time of transplantation, thereby lowering his risk of developing PTLD. Several other studies have demonstrated a positive correlation between the administration of FK506 and the risk of developing PTLD [8, 21, 45, 46] . All but 1 patient in the present study received induction therapy with prednisone, azathioprine (or MMF for kidney-transplant recipients), and cyclosporine (table 2). For 1 of the 6 patients with PTLD, cyclosporine was replaced by FK506 15 days after transplantation; however, this patient also received ATG 3 weeks after transplantation. Of the 14 other high-risk patients, 4 received FK506 but did not develop PTLD.
Effective preemptive therapy for PTLD depends on reliable markers for assessing the risk of developing PTLD. As yet, there is no standard for performing and reporting EBV DNA load measurements. Some laboratories offering this test have derived their own threshold values for determining the risk of developing PTLD by use of quantitative or semiquantitative PCR methods on PBMCs or serum. Hence, interlaboratory comparisons are not feasible. Furthermore, there is seemingly undisputed agreement among the various laboratories offering EBV DNA load analysis that this test, although valuable as a negative predictor of PTLD, is far less accurate as a positive predictor [29] [30] [31] [32] . The laboratory of Saint-Justine Hospital was a pioneer in gauging threshold values for determination of the risk of developing PTLD [28] . By use of a semiquantitative system, it was possible to establish that patients at high risk of developing PTLD had a cutoff value of у1 EBV genomes/1000 PBMCs. The detection efficiency of the assay was 1-10 EBV genomes/input. Nonetheless, 14 of 20 high-risk patients had high EBV DNA loads but did not develop PTLD (table 2) . This low predictability of the EBV DNA load test for the risk of developing PTLD demanded that the system be refined. After reexamining the data, we noted that 7 of these 14 patients had very high EBV DNA loads, as determined by detectability of a specific band in the 1000-cell amplification tube after ethidiumbromide staining alone (indicated by "+++" in table 2). In fact, these 7 patients had band intensity similar to that seen in the 6 patients with PTLD. Thus, even after increasing the EBV DNA load threshold, it would seem that methods based on EBV DNA load evaluation alone overestimate the risk of developing PTLD.
The EBV serologic profile of transplant recipients after primary infection has been examined by several groups [53] [54] [55] [56] [57] [58] [59] . The onset of primary infection in patients from these studies was defined by either serologic testing or molecular diagnosisspecifically, detection by PCR in blood or saliva. It was concluded that (1) the humoral response to EBV was often delayed in these patients; (2) the VCA IgM peak also lagged or failed to appear altogether after primary infection; (3) the VCA IgG antibody response was somewhat delayed after primary infection, but, once detected, these antibodies persisted indefinitely, as is the case in infectious mononucleosis; (4) the lag in the appearance of antibodies to the EBNAs was greater than that associated with primary infection in an immunocompetent individual; and (5) the EA IgG antibodies were not universally seen in transplant recipients experiencing primary infection or reactivation but, when present, persisted for at least several months after transplantation. This delayed humoral response is thought to be reflective of an immune system that is severely depressed by antirejection drugs.
To our knowledge, no correlative study has been published that compares the appearance of EA antibodies with EBV DNA load and the risk of developing PTLD. However, 3 other reports have examined EA antibody titers in transplant recipients. First, Rogers et al. [59] reported that, in their group of 65 transplant recipients, high EBV DNA load was generally accompanied by a statistically significant increase in EA IgG titers. Only 1 of their patients developed PTLD. It is noteworthy that this patient-like the 6 in our study-lacked antibodies to EA. In a second study [15] , low EA antibody titers were observed in 13 patients who developed PTLD; however, in that study, EA titers were not assessed in 115 other transplant recipients who did not develop PTLD. In a third study [58] , EA antibody titers were examined in 10 pediatric liver-transplant recipients with PTLD and in 116 others without PTLD. The investigators observed a progressive increase in EA antibody titers from 14 to 55 between time of transplantation and 24 months after transplantation in patients without PTLD. Patients who developed PTLD had average EA titers of 32 at the time of PTLD diagnosis. These reports did not seek to correlate EA serologic profile with EBV DNA load. In contrast, our present study specifically set out to evaluate the usefulness of EA serologic testing in combination with high EBV DNA load to predict risk of developing PTLD. Our results indicate that, of the 6 patients who had EA titers below the threshold for the risk of developing PTLD (!1 EBV genome/1000 PBMCs), none developed PTLD and none had significant EA antibody titers after primary or reactivated EBV infection. In addition, of the 6 patients with titers above the threshold determined for the risk of developing PTLD (у1 EBV genomes/1000 PBMCs) and who developed PTLD, none had significant EA antibody titers at the time of PTLD diagnosis, although high EA antibody titers eventually were detected in 2 patients at 28 and 64 weeks, respectively, after the diagnosis. This was likely due to a relaxation of the immunosuppressive regimen. Of the 14 other patients with high EBV DNA loads who did not develop PTLD, all 14 had significant increases in their EA antibody titers (у1000 for 12 patients and у100 for 2 patients) at various times after the initial detection of a high EBV DNA load. It is noteworthy that 7 of the 14 patients (patients 4, 5, 11, 12, 13, 14, and 20) had elevated EA antibody titers at the initial appearance of high EBV DNA load (table 2) . These, in fact, would be the patients who stand most to benefit from EA antibody testing, because the serologic assessment indicates that their risk of developing PTLD is low in spite of the high EBV DNA load. Thus, the treating physician would be in a better position to make an informed decision regarding the need to reduce immunosuppressive medication.
In the subgroup of 7 patients without PTLD but with very high EBV DNA loads-as defined by the appearance of EBV DNA on ethidium bromide-stained gels (shown as "+++" in table 2)-5 of the 7 had EA antibody titers у1000 at the time of the initial high EBV DNA load (table 2). The remaining 2 patients developed EA antibodies 11 and 28 weeks later. The latter patient was the only one in this subgroup who had been receiving prophylactic IVIG therapy at the time of high EBV DNA load detection. Indeed, in our original group of 14 patients with high EBV DNA loads, the 3 who were receiving IVIG prophylaxis developed EA antibodies at 23, 28, and 39 weeks (mean, 30.0 weeks) after the first high EBV DNA load peak, whereas the mean time point for the 4 patients not receiving IVIG was 15.3 weeks (range, 6-36 weeks). According to these observations, there seems to be a delay in the development of EA antibodies in the presence of circulating immunoglobulins. Because preparations of hypergammaglobulin for CMV prophylaxis also contain high titers of EA antibody (L.C. and C.A., unpublished observations), it is possible that these products may also contain neutralizing antibodies to EBV, which may affect antibody production by limiting lytic infection. It is worth noting, however, that the high EA antibody titers found in commercial preparations of hypergammaglobulin are not reflected in patients' serum samples when tested in the period immediately after infusion (L.C. and C.A., unpublished observations).
The remaining 7 patients without PTLD had EBV DNA load titers у1000, as determined by use of the more-sensitive system of transfer onto a nylon membrane and hybridization with a labeled probe, rather than by reading the ethidium bromidestained gel directly. The present study has therefore enabled us to redefine the threshold virus burden for high-risk patients so that, in our system, only values у1 EBV genomes/1000 PBMCs, as measured by ethidium-bromide staining, are considered to be alarming. Our results indicate that, on the basis of this determining factor alone, approximately one-half of the patients will develop PTLD. The EA antibody test, when used as a serial complement in cases in which EBV DNA load is high, enables a better prediction of the risk of developing PTLD. At the EBV DNA load threshold at which PTLD occurs, the PPV based on the absence of high titer EA antibody in our small patient group was 75%, meaning that patients with high EBV DNA load but without significant EA antibody titers had a 75% risk of developing PTLD.
The present study is limited by the small patient cohort. The difficulty with such investigations is the requirement for sequential sampling and the relatively low incidence of PTLD, even in a high-risk group. Further reducing the incidence level in the patients we studied is the fact that doctors at SainteJustine Hospital are informed of the EBV DNA load result as soon as it is available. Because of ethical considerations after publication of the study by Savoie et al. [28] , the present study could not have been designed otherwise. A prospective study would require many years before it could accumulate a sufficient number of patients for proper power analysis. Because our laboratory had performed pioneering work in assessing EBV DNA load in transplant recipients [28] , it was possible to rely on some of the stored serum samples from the former study for analysis of the EBV serologic markers. We feel that the results obtained point decidedly to the importance of high EA IgG titers as a second marker that can be used in conjunction with circulating EBV DNA load to evaluate a patient's risk of developing PTLD. Although the absence of у1 of the EBNA antibody classes may also potentially serve to augment the PPV of a high EBV DNA load test [29, 57] , the advantage of testing for EA antibodies is that the latter are not normally found in healthy blood donors. Transplant recipients are often given multiple transfusions that might allow donor antibodies to be detected in the recipient's blood and thus confound the recipient's true serologic status.
Clinically, the EA antibody test would be useful in transplantation centers that perform EBV DNA load testing for assessment of the risk of developing PTLD and that are concerned about the low PPV of their test. The presence of high EBV DNA load with absence of EA antibodies in a transplant recipient should signal the attending physician to closely monitor the evolution of the infection and consider reducing the immunosuppressive medication, to help eradicate the infection and avoid the onset of PTLD.
